Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
1.
Clin Colorectal Cancer ; 23(1): 73-84, 2024 03.
Article in English | MEDLINE | ID: mdl-38151358

ABSTRACT

BACKGROUND: Primary tumor sidedness (PTS) is an independent prognostic factor in patients with metastatic colorectal cancer (CRC), with a worse prognosis for right-sided tumors. There are limited data on the prognostic impact of PTS in stage III CRC. The main objective of this study was to analyze the prognostic impact of PTS in stage III CRC. PATIENTS AND METHODS: A retrospective and uni-institutional cohort study was performed in an oncology reference center. Patients with stage III CRC treated with a 5-fluorouracil and oxaliplatin-based chemotherapy regimen (mFLOX regimen) from October 2007 to February 2013 were included. The primary outcome was the probability of overall survival (OS) at 5 years stratified by PTS. Secondary outcomes were the probability of disease-free survival (DFS) at 5 years and an analysis of the prognostic impact of clinical and molecular biomarkers. Kaplan‒Meier curves were used, and Cox models were used to evaluate prognostic factors associated with OS and DFS. RESULTS: Overall, 265 patients were evaluated. Transverse colon tumors, multicentric tumors, and undetermined primary subsites were excluded, resulting in 234 patients classified according to PTS: 95 with right sidedness (40.6%) and 139 with left sidedness (59.4%). The median follow-up time was 66 months [interquartile range (IQR): 39-81]. The 5-year OS probabilities for right-sided and left-sided tumors were 67% (95% CI: 58%-77%) and 82% (75%-89%), respectively [hazard ratio (HR): 2.02, 95% CI: 1.18-3.46; P = .010]. The 5-year probabilities of DFS for right-sided and left-sided tumors were 58% (49%-69%) and 65% (58%-74%), respectively (HR: 1.29, 0.84-1.97; P = 0.248). CONCLUSION: These data suggest that there may be a worse prognosis (inferior OS at 5 years) for resected right-sided stage III CRC patients treated in the real world. However, these data need to be confirmed by prospective studies with a larger number of participants.


Subject(s)
Colonic Neoplasms , Colorectal Neoplasms , Humans , Prognosis , Cohort Studies , Retrospective Studies , Prospective Studies , Brazil/epidemiology , Colorectal Neoplasms/drug therapy
2.
J Glob Oncol ; 5: 1-6, 2019 09.
Article in English | MEDLINE | ID: mdl-31479339

ABSTRACT

PURPOSE: Conversion chemotherapy is often used for borderline or unresectable (B/U) liver metastases from colorectal cancer (CRC) with the aim of achieving resectability. Although intensive and costly regimens are often used, the best regimen in this scenario remains unclear. We aimed to evaluate the outcomes of patients with B/U liver metastases from CRC treated with conversion chemotherapy with the modified fluorouracil, leucovorin, and oxaliplatin (mFLOX) regimen followed by metastasectomy. METHODS: We performed a single-center retrospective analysis of patients with B/U liver metastases from CRC treated with chemotherapy with the mFLOX regimen followed by surgery. B/U disease was defined as at least one of the following: more than four lesions, involvement of hepatic artery or portal vein, or involvement of biliary structure. RESULTS: Fifty-four consecutive patients who met our criteria for B/U liver metastases were evaluated. Thirty-five patients (64%) had more than four liver lesions, 16 (29%) had key vascular structure involvement, and 16 (29%) had biliary involvement. After chemotherapy, all patients had surgery and 42 (77%) had R0 resection. After a median follow-up of 37.2 months, median progression-free survival (PFS) was 16.9 months and median overall survival (OS) was 68.3 months. R1-R2 resections were associated with worse PFS and OS compared with R0 resection (PFS: hazard ratio, 2.65; P = .007; OS: hazard ratio, 2.90; P = .014). CONCLUSION: Treatment of B/U liver metastases from CRC with conversion chemotherapy using mFLOX regimen followed by surgical resection was associated with a high R0 resection rate and favorable survival outcomes. On the basis of our results, we consider mFLOX a low-cost option for conversion chemotherapy among other options that have been proposed.


Subject(s)
Fluorouracil/therapeutic use , Leucovorin/therapeutic use , Liver Neoplasms/complications , Oxaliplatin/therapeutic use , Adult , Aged , Colorectal Neoplasms , Fluorouracil/pharmacology , Humans , Leucovorin/pharmacology , Middle Aged , Neoplasm Metastasis , Oxaliplatin/pharmacology , Retrospective Studies , Young Adult
3.
Autops Case Rep ; 4(1): 45-51, 2014.
Article in English | MEDLINE | ID: mdl-28652992

ABSTRACT

Mesothelioma of the tunica vaginalis testis (MTVT) is a rare tumor that usually affects patients after the sixth decade of life. Exposure to asbestos is a known risk factor. Enlargement of the scrotal volume is the most common initial clinical manifestation, and about 15% of cases present metastasis at diagnosis. The treatment relies on surgical resection while the role of adjuvant chemotherapy and radiotherapy remains unclear. The prognosis for patients is generally poor, with a lethal outcome in 30% over a 24-month period. The authors report a case of a 62-year-old patient with the diagnosis of MTVT without a history of asbestos exposure. After surgical treatment, metastatic disease ensued. Chemotherapy was initiated, but could not be continued due to marked and fast clinical deterioration. The authors call attention to the difficulty of early diagnosis of MTVT due to a nonspecific clinical picture, the lack of action by the patient when the scrotal enlargement was first noticed, and the lack of tumor markers. Delayed diagnosis is definitely related to unfavorable prognosis.

5.
Rev. bras. anestesiol ; 53(2): 227-236, mar.-abr. 2003. graf
Article in Portuguese | LILACS | ID: lil-351768

ABSTRACT

JUSTIFICATIVA E OBJETIVOS: A incidência de Obesidade Mórbida tem aumentado significativamente nas últimas décadas, especialmente nos países desenvolvidos. Os excelentes resultados observados com o tratamento cirúrgico desta condiçäo têm feito ressurgir o interesse no manuseio anestésico deste grupo de pacientes. O objetivo deste estudo foi enfatizar pontos vitais para o anestesiologista que lida com tais pacientes. CONTEUDO: Distúrbios cardiovasculares, respiratórios, endócrinos e metabólicos säo freqüentemente associados à obesidade e podem causar repercussöes de significado clínico importantes no período peri-operatório nestes pacientes. Alguns aspectos de interesse prático à anestesia säo discutidos nesta revisäo. CONCLUSÖES: Além da ênfase dada às complicaçöes mais importantes e mais freqüentemente observadas e de como preveni-las, destacamos também a importância do uso do PEEP e de volumes correntes adequados, recomendando seu uso


Subject(s)
Humans , Bariatric Surgery , Anesthesia, General/instrumentation , Postoperative Period , Obesity, Morbid , Preoperative Period
6.
Rev Bras Anestesiol ; 53(2): 227-36, 2003 Apr.
Article in Portuguese | MEDLINE | ID: mdl-19475275

ABSTRACT

BACKGROUND AND OBJECTIVES: The incidence of morbid obesity has significantly increased in recent years, especially in developed countries. Excellent results of the surgical treatment of such condition have raised the interest in the anesthetic management of such patients. This study aimed at emphasizing critical issues for anesthesiologists dealing with morbidly obese patients. CONTENTS: Cardiovascular, respiratory, endocrine and metabolic changes have been frequently associated to obesity and may cause significant clinical repercussions in the perioperative period of such patients. Some practical anesthetic issues are discussed in this review. CONCLUSIONS: In addition to emphasizing most significant and frequent complications and their prevention, the importance of PEEP and adequate tidal volumes is also highlighted.

SELECTION OF CITATIONS
SEARCH DETAIL
...